期刊文献+

晚期乳腺癌不同的化疗方法疗效比较 被引量:8

Comparison on Therapeutic Effect of Different Chemotherapy in Locally Advanced Breast Cancer
下载PDF
导出
摘要 目的探讨新辅助化疗不同的治疗方案对局部晚期乳腺癌患者的疗效。方法75例接受新辅助化疗的乳腺癌(A期)患者随机分为三组:TA组(n=25,紫杉醇联合吡柔比星),CAF组(n=25,吡柔比星联合环磷酰胺、5-氟尿嘧啶),CMF组(n=25,环磷酰胺联合5-氟尿嘧啶、氨甲喋呤),21d为一个周期,两个周期后对乳腺癌原发病灶及腋窝淋巴结状态进行观察及分析。结果TA组、CMF组和CAF组总有效率分别为83%、63%和25%。TA组与CMF组相比较有显著差异(P<0.05),CAF组与CMF组相比较有显著差异(P<0.05),TA组与CAF组相比较无统计学意义(t=0.022,P>0.05)。结论TA组和CAF组在局部晚期的乳腺癌新辅助治疗的过程中疗效满意,毒副反应可以耐受,值得推广。 Objective To discuss the therapeutic effect of different chemotherapy in the treatment of advanced breast cancer. Methods Seventy-five patients with advanced breast cancer receiving different newly developed chemotherapy were randomly divided into three groups: Group TA(n=25, paclitaxel and pirarubicin), Group CAF(n = 25, pirarubicin, cyclophosphamide and 5-fluorouracil) and Group CMF(n = 25, cyclophos-phamide, 5-fluorouracil and metholrexate), each therapeutic course was completed within 21 days. The primary breast cancer and axillary lymphadenopathy were observed at the end after therapeutic courses completed. Results The effective rates of TA, CAF and CMF were 83%, 63%, 25%, respectively. There were significant differences between the TA and CMF groups(P 〈 0.05) and also between the CAF and CMF groups(P〈 0.05), but not between the TA and CAF groups(P〉 0.05). Conclusion Group TA and group CAF have satisfactory effect.
出处 《中国现代医生》 2007年第12S期19-20,共2页 China Modern Doctor
关键词 乳腺癌 化疗 Advanced breast cancer, Chemotherapy
  • 相关文献

参考文献4

二级参考文献27

  • 1沈镇宙,柳光宇,苏逢锡,何萍青,杨名添,施俊义,盛援,邹强,李亚芬.多西紫杉醇加表柔比星治疗局部晚期乳腺癌的多中心Ⅱ期临床研究[J].中华肿瘤杂志,2005,27(2):126-128. 被引量:56
  • 2[1]Inaji H, Komoike Y, Motomura K, et al. Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer[J]. Breast Cancer, 2002, 9(1):20~25
  • 3[2]Newman LA, Buzdar AU, Singletary SE, et al. A prospective trial of preoperative chemotherapy in resectable breast cancer:predictors of breast-conservation therapy feasibility [J]. Ann Surg Oncol, 2002, 9(3):217~219
  • 4[3]Kuerer HM, Singletary SE, Brzdar AU, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage Ⅱ and operable stage Ⅲ breast carcinoma[J]. Am J Surg, 2001,182(6):601~608
  • 5[4]Baslaim MM, A1 Malik OA, Al Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy[J]. Am J Surg, 2002, 184 (4): 299~301
  • 6[5]Gradishar WJ. Primary (neoadjuvant) chemotherapy with docetaxel in breast cancer[J]. Clin Breast Cancer, 2001, 2(Suppl 1):S31~35
  • 7[6]Smith IC, Heys SD, Hutcheon AW, et al, Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel[J]. J Clin Oncol 2002, 20 (6): 1456~1466
  • 8[7]De Matteis A, Nuzzo F, D'Aiuto G. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase Ⅱ study[J]. Cancer, 2002,94(4):895~901
  • 9[8]Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage Ⅲ primary breast cancer with primary chemotherapy,surgery, and radiation therapy[J]. Cancer, 1988, 62(12):2507~2516
  • 10[9]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997, 15:2483~2495

共引文献66

同被引文献67

引证文献8

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部